Droxidopa, an oral norepinephrine precursor, improves hemodynamic and renal alterations of portal hypertensive rats

Hepatology

Volumn 56, Issue 5, 2012, Pages 1849-1860

  Coll, Mar ^a   Rodriguez, Sarai ^a   Raurell, Imma ^a   Ezkurdia, Nahia ^a   Brull, Astrid ^a   Augustin, Salvador ^a   Guardia, Jaime ^a,b   Esteban, Rafael ^a,b   Martell, María ^a   Genescà, Joan ^a,b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON TETRACHLORIDE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; PROTEIN KINASE B; RHO KINASE; THREO 3,4 DIHYDROXYPHENYLSERINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTERY RESISTANCE; ARTICLE; BILE DUCT; BLOOD ANALYSIS; CONTROLLED STUDY; DIURESIS; DRUG MECHANISM; ENZYME ACTIVITY; HEMODYNAMIC PARAMETERS; KIDNEY BLOOD FLOW; LIVER BLOOD FLOW; LIVER CIRRHOSIS; LIVER FUNCTION; MALE; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; RAT; SHAM PROCEDURE; SUPERIOR MESENTERIC ARTERY; URINALYSIS; WESTERN BLOTTING;

ANIMALS; ANTIPARKINSON AGENTS; BILE DUCTS; BLOOD PRESSURE; CARBIDOPA; CARBON TETRACHLORIDE; DISEASE MODELS, ANIMAL; DIURESIS; DROXIDOPA; ENZYME INHIBITORS; HEMODYNAMICS; HYPERTENSION, PORTAL; LIGATION; LIVER CIRRHOSIS; MALE; NATRIURESIS; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; PORTAL VEIN; PROPRANOLOL; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; REGIONAL BLOOD FLOW; RENAL CIRCULATION; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION; URODYNAMICS; VASCULAR RESISTANCE;

EID: 84868191182     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25845     Document Type: Article

References (28)

1. Arroyo V, Fernandez J, Gines P. Pathogenesis and treatment of hepatorenal syndrome. Semin Liver Dis 2008; 28: 81-95.
2. Gines P, Schrier RW. Renal failure in cirrhosis. N Engl J Med 2009; 361: 1279-1290.
3. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. HEPATOLOGY 1988 Sep; 8: 1151-1157.
4. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: From the patient to the molecule. HEPATOLOGY 2006; 43: S121-S131.
5. Martell M, Coll M, Ezkurdia N, Raurell I, Genesca J. Physiopathology of splanchnic vasodilation in portal hypertension. World J Hepatol 201; 2: 208-220.
6. Rodriguez-Vilarrupla A, Fernandez M, Bosch J, Garcia-Pagan JC. Current concepts on the pathophysiology of portal hypertension. Ann Hepatol 2007; 6: 28-36.
7. Coll M, Genesca J, Raurell I, Rodriguez-Vilarrupla A, Mejias M, Otero T, et al. Down-regulation of genes related to the adrenergic system may contribute to splanchnic vasodilation in rat portal hypertension. J Hepatol 2008; 49: 43-51.
8. Coll M, Martell M, Raurell I, Ezkurdia N, Cuenca S, Hernandez-Losa J, et al. Atrophy of mesenteric sympathetic innervation may contribute to splanchnic vasodilation in rat portal hypertension. Liver International 2010; 30: 593-602.
9. Gines P, Cardenas A. The management of ascites and hyponatremia in cirrhosis. Semin Liver Dis 2008; 28: 43-58.
10. Sola E, Gines P. Renal and circulatory dysfunction in cirrhosis: current management and future perspectives. J Hepatol 2010; 53: 1135-1145.
11. Goldstein DS. L-Dihydroxyphenylserine (L-DOPS): a norepinephrine prodrug. Cardiovasc Drug Rev 2006; 24: 189-203.
12. Kaufmann H. L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience. Clin Auton Res 2008; 18( Suppl 1): 19-24.
13. Mathias CJ. L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience. Clin Auton Res 2008; 18( Suppl 1): 25-29.
14. Oria M, Raguer N, Chatauret N, Bartoli R, Odena G, Planas R, et al. Functional abnormalities of the motor tract in the rat after portocaval anastomosis and after carbon tetrachloride induction of cirrhosis. Metab Brain Dis 2006; 21: 297-308.
15. Hennenberg M, Trebicka J, Sauerbruch T, Heller J. Mechanisms of extrahepatic vasodilation in portal hypertension. Gut 2008; 57: 1300-1314.
16. Araki H, Tanaka C, Fujiwara H, Nakamura M, Ohmura I. Pressor effect of L-threo-3, 4-dihydroxyphenylserine in rats. J Pharm Pharmacol 1981; 33: 772-777.
17. Katsube J, Kato T, Katsuyama M, Maeda Y, Nishikawa S, Nakamura M. Diuretic effect of L-threo-3, 4-dihydroxyphenylserine, a noradrenaline precursor, in rats and mice. J Pharm Pharmacol 1986; 38: 533-534.
18. Morimoto S, Matsumura Y, Ohyama T, Shinyama H, Ichihara T, Takahashi Y, et al. Diuretic effects of L-threo-3, 4-dihydroxyphenylserine (L-threo-DOPS) in anesthetized rats. Jpn J Pharmacol 1990; 52: 431-439.
19. Goldstein DS, Holmes C, Kaufmann H, Freeman R. Clinical pharmacokinetics of the norepinephrine precursor L-threo-DOPS in primary chronic autonomic failure. Clin Auton Res 2004; 14: 363-368.
20. Ming X-F, Viswambharan H, Barandier C, Ruffieux J, Kaibuchi K, Rusconi S, et al. Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol Cell Biol 2002; 22: 8467-8477.
21. Trebicka J, Hennenberg M, Laleman W, Shelest N, Biecker E, Schepke M, et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. HEPATOLOGY 2007; 46: 242-253.
22. Michel MC, Rump LC. Alpha-adrenergic regulation of human renal function. Fundam Clin Pharmacol 1996; 10: 493-503.
23. Gellai M. Modulation of vasopressin antidiuretic action by renal alpha 2-adrenoceptors. Am J Physiol 1990; 259( 1 Pt 2): F1-F8.
24. Stadlbauer V, Wright GA, Banaji M, Mukhopadhya A, Mookerjee RP, Moore K, et al. Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis. Gastroenterology 2008; 134: 111-119.
25. Martinez-Prieto C, Ortiz MC, Fortepiani LA, Ruiz-Macia J, Atucha NM, Garcia-Estan J. Haemodynamic and renal evolution of the bile duct-ligated rat. Clin Sci (Lond) 2000; 98: 611-617.
26. Pereira RM, dos Santos RA, Oliveira EA, Leite VH, Dias FL, Rezende AS, et al. Development of hepatorenal syndrome in bile duct ligated rats. World J Gastroenterol 2008; 14: 4505-4511.
27. Lenzen R, Funk A, Kolb-Bachofen V, Strohmeyer G. Norepinephrine-induced cholestasis in the isolated perfused rat liver is secondary to its hemodynamic effects. HEPATOLOGY 1990; 12: 314-321.
28. Oben JA, Roskams T, Yang S, Lin H, Sinelli N, Torbenson M, et al. Hepatic fibrogenesis requires sympathetic neurotransmitters. Gut 2004; 53: 438-445.